ENTA · Enanta Pharmaceuticals Inc
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-23 |
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
MAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis; Early Diagnosis and Treatment Help Reduce Transmission, Long-Term |
| 2026-06-18 |
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 WATERTOWN, Mass. |
| 2026-05-28 |
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass. --(BUSINESS WIRE)--May 28, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. |
| 2026-05-11 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus |
| 2026-05-04 |
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
WATERTOWN, Mass. --(BUSINESS WIRE)--May 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation |
| 2026-04-13 |
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026 WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 13, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated |
| 2026-04-07 |
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 7, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein |
| 2026-03-30 |
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)
WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 30, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company’s STAT6 inhibitor |
| 2026-03-03 |
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 3, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside |
| 2026-02-10 |
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 10, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-04 | Jefferies Global Healthcare Conference | Conference |
| 2026-03-11 | 2026 Annual Meeting | Shareholder meeting |
| 2026-03-10 | The Citizens Life Sciences Conference | Conference |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2025-12-03 | 8th Annual Evercore Healthcare Conference | Conference |
| 2025-11-18 | Jefferies Global Healthcare Conference in London | Conference |
| 2025-09-29 | Enanta Pharmaceuticals RSVHR Study Results Call | Earnings call |
| 2025-09-10 | Baird 2025 Global Healthcare Conference | Conference |
| 2025-09-09 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-09-03 | Cantor Global Healthcare Conference 2025 | Conference |
Source: https://ir.enanta.com/